LIST OF REPORTS
SCIENCE AND TECHNOLOGY COMMITTEE REPORTS IN THE CURRENT PARLIAMENT
Session 1997-98
First Report: The Implications of the Dearing Report
for the Structure and Funding of University Research (HC 303)
Second Report: The Year 2000—Computer Compliance
(HC 342)
Third Report: Glaxo Wellcome and SmithKline Beecham:
The Merger Proposals (HC 627)
Fourth Report: The Cloning of Animals from Adult
Cells (HC 1039)
Fifth Report: British Biotech (HC 888)
Sixth Report: Science and the Comprehensive Spending
Review (HC 1040)
First Special Report: The Government's Response to
the Committee's Fourth Report, Session 1996-97, The Research Council
System: Issues for the Future (HC 302)
Second Special Report: The Government's Response
to the Committee's Third Report, Session 1996-97, The Natural
Environment Research Council and Research into Climate Change
(HC 306)
Third Special Report: The Government's Response to
the Committee's First Report, Session 1997-98, The Implications
of the Dearing Report for the Structure and Funding of University
Research (HC 799)
Fourth Special Report: The Government's Response
to the Committee's Fifth Report, Session 1997-98, British Biotech
(HC 1185)
Session 1998-99
First Report: The Scientific Advisory System: Genetically
Modified Foods (HC 286)
Second Report: The National Endowment for Science,
Technology and the Arts (HC 472)
Third Report: The Scientific Advisory System: Mobile
Phones and Health (HC 489)
Fourth Report: The Regulation of the Biotechnology
Industry (HC 535)
First Special Report: The Government's Response to
the Committee's Sixth Report, Session 1997-98, Science and the
Comprehensive Spending Review (HC 234)
Second Special Report: The Government's Response
to the Committee's Second Report, The National Endowment for Science,
Technology and the Arts (HC 822)
Session 1999-2000
First Report: The Year 2000—Computer Compliance:
Follow-Up (HC 37)
Second Report: Engineering and Physical Sciences
Based Innovation (HC 195-I)
Third Report: Scientific Advisory System: Diabetes
and Driving Licences (HC 206-I)
Fourth Report: Glaxo Wellcome and SmithKline Beecham
(HC 207-I)
Fifth Report: Government Expenditure on Research
and Development: The Forward Look (HC 196-I)
Sixth Report: Cancer Research—A Fresh Look
(HC 332-I)
Seventh Report: The Government's Expenditure on Research
and Development: The Forward Look—The Government's Reply
(HC 723)
First Special Report: Government Response to the
Committee's Second Report, Engineering and Physical Sciences Based
Innovation (HC 451)
Second Special Report: Joint Working with the Lords
Science and Technology Committee (HC 980)
Third Special Report: Government Response to the
Seventh Report of the Science and Technology Committee on the
Government's Expenditure on Research and Development: The Forward
Look—The Government's Reply (HC 981)
Session 2000-2001
First Report: EQUAL (Extend Quality Life) (HC 43)
Second Report: Corus plc—Research and Development
(HC 110)
Third Report: Scientific Advisory System: Scientific
Advice on Climate Change (HC 14)
Fourth Report: The Scientific Advisory System (HC
257)
First Special Report: The Work of the Science and
Technology Committee 1997-2000 (HC 44)
| 
